scorecardresearch
Wednesday, July 23, 2025
TopicAlzheimer

Topic: Alzheimer

How semaglutide is emerging as A-Z drug, helping with diabetes, alcohol cravings & more

Health experts are now looking at whether semaglutide can also curb alcohol cravings among addicts. A look at how this GLP-1 category drug functions in humans.

There is a huge treatment gap for neurological conditions like Alzheimer’s—how to close it

Health inequities compound the problem, with people living in rural or poor communities disproportionately affected. The coverage of publicly funded medicines needs to be improved.

How a protein fragment in the brain & spinal fluid may simplify tracking Alzheimer’s progression

Researchers have identified a fragment of tau protein called MTBR-tau243. Tracking it, instead of the entire protein, may make monitoring Alzheimer's easier & less dependent on complex imaging.

Alzheimer’s can be diagnosed as early as 30—and symptoms aren’t what you’d expect

Those living with young-onset Alzheimer’s disease show more rapid – and aggressive – changes in their brain.

Alzheimer was a doctor who discovered a ‘special illness’ in his 50-year-old German patient

In ‘My Father’s Brain’, Sandeep Jauhar recounts his parent’s experience with Alzheimer’s while delving into the history – and fallout – of the disease.

‘Rare’ genetic mutation linked to Alzhiemer’s resistance in international study 

In study published in 'Nature Medicine' Monday, researchers from Colombia, Germany, & US cite case of a 67-yr-old whose cognition remained intact despite having genetic markers for Alzheimer's.

New Alzheimer’s drug Lecanemab shows promising results, but raises several questions

While lecanemab saw less decline in cognition and function of patients, the drug is effective only at a very early stage -- closer to the onset of the disease.

More accurate way to predict who will develop Alzheimer’s disease – new study

With the fast progression of research in biomarkers, we are quickly getting better at measuring and detecting early signs of Alzheimer’s.

Why US approval of Alzheimer’s drug has divided doctors over its effectiveness & uses

Despite the divide, having the drug on the market will change Alzheimer’s care, at least for some patients, and the FDA’s green light might pave the way for future therapies.

Why this woman in Colombia didn’t develop Alzheimer’s despite being at great risk for it

ScientiFix, our weekly feature, offers you a summary of the top global science stories of the week, with links to the best sources to read them.

On Camera

Modi govt has learned from past FTAs. Its priority now is building a manufacturing powerhouse

Past FTAs failed to yield much benefit because they exposed domestic industries to global competition without strengthening the manufacturing ecosystem.

India-US set to ink mini trade deal soon, reach understanding on agricultural & dairy products

Mini deal will likely see no cut in 10% baseline tariff on Indian exports announced by Trump on 2 April, it is learnt, but additional 26% tariffs are set to be reduced.

Indian firm sets up titanium, superalloy plants to meet global need. Safran, Dassault, BAE line up

PTC Industries is investing Rs 1,000 cr in 4 manufacturing plants in UP, has already started supplying titanium parts to BAE Systems for its M-777 howitzers that India also uses.

Strategic partner one day, tactical nightmare the next: India’s learning Trumplomacy the hard way

Public, loud, upfront, filled with impropriety and high praise sometimes laced with insults. This is what we call Trumplomacy. But the larger objective is the same: American supremacy.